Top 50 Biotech Startup Investors in Denmark (October 2023)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
24 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.5M–$125M |
|
BioInnovation Institute
VC Fund
|
18 | Denmark, Germany, Switzerland | Convertible Note, Debt Financing, Pre-Seed | Biotechnology, Medical, Health Care | $504k–$1.8M |
|
Vaekstfonden
VC Fund
|
15 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $431k–$4.6M |
|
Seed Capital
VC Fund
|
9 | Denmark, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $500k–$19M |
|
Sunstone Life Science Ventures
VC Fund
|
9 | Denmark, Sweden, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $5.1M–$136M |
|
PreSeed Ventures
VC Fund
|
6 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $86k–$3.3M |
|
Nordic Foodtech VC
VC Fund
|
5 | Finland, Denmark, Sweden | Seed, Series A | Biotechnology, Seafood, Life Science | $321k–$4.3M |
|
Gilde Healthcare
VC Fund
|
4 | United States, The Netherlands, Germany | Series C, Series B, Series A | Biotechnology, Health Care, Medical | $8M–$60M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A | Software, Biotechnology, SaaS | $1.2M–$22M |
|
Oskare Capital
VC Fund
|
3 | Italy, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Medical | |
|
RA Capital Management
VC Fund
|
3 | United States, United Kingdom, China | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $24M–$200M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.4M–$57M |
|
Ysios Capital
VC Fund
|
3 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.1M–$48M |
|
HealthCap
VC Fund
|
3 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.5M–$55M |
|
EIR Ventures
VC Fund
|
3 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $30M–$73M |
|
Novo Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $8.4M–$75M |
|
Nicholas Francis
Angel
|
2 | Denmark, United States | Seed | SaaS, Robotics, Software | $862k–$7.1M |
|
Novo Nordisk
VC Fund
|
2 | Denmark, United States, France | Series A, Series C, Seed | Biotechnology, Medical, Biopharma | $5M–$21M |
|
Blue Horizon Corporation
VC Fund
|
2 | United States, United Kingdom, France | Seed, Series A | Food and Beverage, Food Processing, Biotechnology | $614k–$21M |
|
West Hill Capital
VC Fund
|
2 | United Kingdom, Denmark | Seed, Series A | Information Technology, Software, Health Care | $1.2M–$15M |
|
Northzone
VC Fund
|
2 | United States, Sweden, United Kingdom | Series A, Series B, Seed | Software, E-Commerce, Information Technology | $2.3M–$52M |
|
Atlantic Labs
VC Fund
|
2 | Germany, Switzerland, United States | Seed, Series A, Pre-Seed | Health Care, Software, Information Technology | $850k–$27M |
|
The Yield Lab Europe
VC Fund
|
2 | Ireland, United Kingdom, France | Seed, Series A | AgTech, Agriculture, Biotechnology | $536k–$10M |
|
Aescap Venture
VC Fund
|
2 | United Kingdom, Austria, Belgium | Series A, Series B | Biotechnology, Pharmaceutical, Chemical | $4.9M–$24M |
|
Innovations Kapital
VC Fund
|
2 | Sweden, Denmark, United States | Series B, Series C | Biotechnology, Health Care, Software | $5.5M–$30M |
|
Wellington Partners
VC Fund
|
2 | Germany, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $3M–$43M |
|
Innovation Fund Denmark
VC Fund
|
2 | Denmark, United States | Grant, Pre-Seed, Seed | Software, SaaS, Information Technology | $30k–$2M |
|
FundersClub
VC Fund
|
2 | United States, Canada, India | Seed, Series A | Software, SaaS, Information Technology | $600k–$23M |
|
CAPNOVA
VC Fund
|
2 | Denmark, United States, India | Seed, Pre-Seed | Software, Information Technology, Internet | $144k–$2.3M |
|
DSM Venturing
VC Fund
|
2 | United States, Canada, Israel | Series A, Series B | Biotechnology, Health Care, Manufacturing | $2.5M–$23M |
|
Industrifonden
VC Fund
|
2 | Sweden, United States, Denmark | Series A, Seed | Software, Biotechnology, Information Technology | $1.3M–$14M |
|
M Ventures
VC Fund
|
2 | United States, Switzerland, United Kingdom | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.1M–$67M |
|
Lundbeckfonden Ventures
VC Fund
|
2 | United States, United Kingdom, France | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $8M–$50M |
|
Bruce Linton
Angel
|
2 | Canada, United States, Denmark | Seed, Post-IPO Equity, Pre-Seed | Health Care, Cannabis, Biotechnology | $6M–$53M |
|
Karolinska
VC Fund
|
2 | Sweden, Denmark, United States | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $1.3M–$73M |
|
Johnson & Johnson Development Corporation
VC Fund
|
2 | United States, United Kingdom, Canada | Series C, Series B, Series A | Health Care, Biotechnology, Medical | $9M–$43M |
|
Per Falholt
Angel
|
1 | Denmark | Seed | Robotics, Biotechnology, Industrial Automation | |
|
ACME Capital
VC Fund
|
1 | United States, Denmark, Canada | Seed, Series A, Series B | Software, Health Care, Information Technology | $1.6M–$100M |
|
Ferd
VC Fund
|
1 | Norway, Sweden, United States | Private Equity, Post-IPO Equity | Energy, Software, Manufacturing | $1M–$38M |
|
NOON Ventures
VC Fund
|
1 | Denmark | Seed | Electronics, Biotechnology, Semiconductor | |
|
Sound Bioventures
VC Fund
|
1 | Denmark, United States | Seed, Series A | Medical, Biopharma, Life Science | |
|
People Ventures
VC Fund
|
1 | Denmark, Sweden, United States | Seed, Pre-Seed, Series A | Health Care, Internet of Things, Software | $1.4M–$21M |
|
Four Seasons Ventures
VC Fund
|
1 | Denmark, United States, United Kingdom | Series B, Series D | Legal, Software, Analytics | |
|
North-East Healthcare Investment
VC Fund
|
1 | Denmark | Series A | Therapeutics, Biotechnology, Medical Device | |
|
GGV Capital
VC Fund
|
1 | United States, China, Singapore | Series B, Series A, Series C | Software, Information Technology, Artificial Intelligence | $5M–$134M |
|
Rhia Ventures
VC Fund
|
1 | United States, Canada, Israel | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Women's | $11M–$15M |
|
SR One
VC Fund
|
1 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$85M |
|
Alta Partners
VC Fund
|
1 | United States, United Kingdom, Spain | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $5.2M–$109M |
|
Balderton Capital
VC Fund
|
1 | United Kingdom, United States, Germany | Series A, Series B, Series C | Software, FinTech, Financial Services | $3.5M–$85M |
|
Index Ventures
VC Fund
|
1 | United States, United Kingdom, France | Series A, Series B, Seed | Software, E-Commerce, Internet | $1.2M–$50M |
| Access all 50 investors in Denmark Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 225
- Round size: Series A $6.5M–$63M; Series B $12M–$125M; Series C $12M–$105M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Octave — Octave is a national behavioral health practice that’s creating a new standard for care delivery that’s both high-quality and accessible to more people. With in-person and virtual clinics in California and New York, the company offers personalized care plans that can include individual therapy, couples therapy, and groups, while pioneeringrelationships with payers to make care more affordable through insurance. Grounded in science, Octave enables clients to experience profound change that is as measurable as it is meaningful.
- Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
- Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Debt Financing, Pre-Seed
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 65
- Round size: Pre-Seed $504k–$1.8M; Debt Financing $536k–$1.4M; Convertible Note $536k–$1.4M
- Lead/follow: 92% lead, 8% follow
Portfolio highlights
- TriptoBIO — TriptoBIO is developing a platform for producing natural plant compounds that will support the health of our planet. Our goal is to create a future where everyone can benefit from the power of plants, without depleting natural resources. Our first compound will liberate the world from rat poison
- MATR Foods — MATR Foods is a food-tech startup that provides fungi-based food ingredients offering dishes produced from fungi like mushrooms, vegetables, and fruits.
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 188
- Round size: Seed $790k–$4.6M; Pre-Seed $431k–$1.2M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
- QuadSAT — QuadSAT provides antenna and RF measurements with state-of-the-art equipment, including a drone platform with payload and custom software.
- kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 166
- Round size: Seed $500k–$4.8M; Series A $3.8M–$19M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $67M in 2021
Portfolio highlights
- Embla — Embla provides an online medical weight loss treatment using prescription drugs and coaching. The company provides patients with evidence-based treatments, digital tools, medication, and coaching to facilitate sustainable weight loss. Embla was founded in 2021 and is headquartered in Copenhagen, Denmark.
- Lunar — Get a free account and card - just like 750,000 others. Spend smart. Achieve financial peace of mind. Sign up in minutes.
- Landfolk — Landfolk is the new marketplace for the special holiday homes that are hidden around the country. We have hand-picked every single cottage, where there are proud and passionate hosts, who love their holiday homes, but also like to share it with others.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 53
- Round size: Series A $5.1M–$42M; Series B $9.6M–$136M
- Lead/follow: 15% lead, 85% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
PreSeed Ventures is the biggest and most succesful early stage investor in Denmark. For more than 20 years, PreSeed Ventures have assisted and financed talented entrepreneurs with early-stage investments, and we hold more than 70 companies in our portfolio.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 119
- Round size: Seed $500k–$3.3M; Pre-Seed $86k–$1.7M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $38M in 2020
Portfolio highlights
- Jabbr — Jabbr allows to capture boxing matches with a virtual video production.Its goal is to make video production and advanced performance analytics in combat sports available to anyone with a smartphone.
- Marts — Marts is an integrated platform that enhances the capacities of IT departments by eliminating these inefficiencies. Put unconnected systems and intimidating spreadsheets behind. IT asset management, support services, and procurement are all integrated into one platform by Marts.
- NORTHSTAKE — Providing institutional investors with access to future economies through secure and trustworthy investment pathways for digital assets
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more...Investment focus
- Industry: Biotechnology, Seafood, Life Science
- Stage:Seed, Series A
- Geography: Finland, Denmark, Sweden
Investor stats
- Total investments: 18
- Round size: Seed $321k–$4.3M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- ÄIO — Innovative food technologies to replace palm oil, coconut oil and animal fats with sustainable and healthier alternatives.
- eniferBio — Enifer Bio is an expert at squeezing every last drop of value from biorefining operations. The solution is built on decades of Finnish expertise to allow the production of valuable protein-rich feed from streams previously considered worthless. The company has developed a new, sustainable production process for high-quality fish feed raw material.The company's method enables the efficient production of a single cell protein from fish by-products as a raw material for fish feed. The protein can replace soy, which is commonly used in fish feed and whose cultivation poses ecological challenges, such as deforestation in South America.
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series C, Series B, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 100
- Round size: Series A $8.6M–$47M; Series B $8M–$60M; Series C $21M–$50M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- GT Medical Technologies — At GT Medical Technologies, our purpose is Improving the Lives of Patients with Brain Tumors. GammaTile Therapy is Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 28
- Round size: Seed $1.2M–$8.9M; Series A $5.5M–$22M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.
Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Pre-Seed, Series A
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 5
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 275
- Round size: Series A $26M–$151M; Series B $24M–$135M; Series C $30M–$200M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
- SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 232
- Round size: Series A $4.4M–$53M; Series B $7M–$57M; Series C $10M–$54M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
- Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
- Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 65
- Round size: Series A $2.1M–$40M; Series B $17M–$37M; Series C $27M–$48M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 109
- Round size: Series A $5.5M–$55M; Series B $20M–$54M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Hemab — Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 9
- Round size: Series A $30M–$73M
- Lead/follow: 56% lead, 44% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- Synklino — Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
- Pretzel Therapeutics — Welcome To A New Era In Mitochondrial Therapeutics. Developing treatments to address the genetic roots of mitochondrial dysfunction.
Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established in 1999 prior to the demerger of Novo NordiskA/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia.Novo A/S attains these objectives through:compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad.Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets.Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group.The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 77
- Round size: Series A $8.4M–$49M; Series B $18M–$75M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- INBRACE — Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.
- Theraxyte — Theraxyte is an innovative nano-drug developer. It focuses on the R&D and application of new nano-drugs, especially innovative drugs.
- Amolyt Pharma — We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
Nicholas Francis is Co-founder at framebunker
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 3
- Round size: Seed $862k–$7.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan is a SaaS platform for companies to manage water availability in their facilities.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Series A, Series C, Seed
- Geography: Denmark, United States, France
Investor stats
- Total investments: 9
- Round size: Series A $5M–$12M; Series C $16M–$21M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Sundew — Targeting water-borne pests and diseases
- The Sabi — Holistic, all natural skincare and herbal remedies for hormonal balancing. SABI represents a path to feeling well and beautiful, a place for key knowledge transfer and the essential self-care rituals to navigate the female hormonal journey.
- ElevateBio — We provide the tools, time, and environment to innovate and accelerate development of life-saving Cell and gene therapies.
Our mission is to accelerate the transition to a new Sustainable Food System that delivers outstanding returns for investors and the planet.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 90
- Round size: Seed $614k–$12M; Series A $1.5M–$21M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- WOW EARN — WOW EARN connects users to the blockchain, enabling them to mine, earn, and trade via decentralised mining, earning, and trading systems.
- New School Foods — Whole-muscle, plant-based seafood
- Basecamp Research — Novel proteins from nature. We sample the most extreme and exciting places on the planet to build the world's largest knowledge graph of natural biodiversity.
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, Denmark
Investor stats
- Total investments: 37
- Round size: Seed $1.2M–$5.5M; Series A $1.8M–$15M
- Lead/follow: 86% lead, 14% follow
Portfolio highlights
- Skyline Partners — Skyline Partners | Closing the Global Coverage Gap through Innovative Parametric Insurance Solutions.
- ATLANT 3D Nanosystems — Micro and nanodevices are built and tested within days instead of months or years.
- Whistleblower Software — A Whistleblower Software system made for accountants and lawyers that have clients, the whistleblower software system helps businesses implement a compliant solution that is both secure and transparent. their products are reporting links, case management, partner account they have designed a journey that makes feel safe about the process. AWS ishandling the physical security of the infrastructure, whistleblower software takes the shared responsibility of security between our cloud infrastructure and application seriously.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Northzone is a venture capital fund with a perspective shaped by lives as entrepreneurs. Since 1996, they've made over 175 investments and invest from Seed to Growth. They've partnered with the founders of Spotify, Avito, iZettle, Klarna, Hopin, and hundreds of others to build category-defining businesses. They've raised €1bn inSeptember 2022.
Show more...Investment focus
- Industry: Software, E-Commerce, Information Technology
- Stage:Series A, Series B, Seed
- Geography: United States, Sweden, United Kingdom
Investor stats
- Total investments: 239
- Round size: Seed $2.3M–$11M; Series A $3.2M–$25M; Series B $5M–$52M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- IDOVEN — IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
- Quench.ai — Quench is a tech infrastructure for video creators to deliver exclusive content, engage and reward their true fans.
- Bedrock Ocean Exploration — Bedrock is building smarter, more efficient ways to collect and manage seafloor data.
Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures. <br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 156
- Round size: Seed $1.1M–$5.6M; Pre-Seed $850k–$1.3M; Series A $4.6M–$27M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- SureIn — small business insurance manager
- Colonia — Colonia is a logistics company that brings all global trucks and trailers into one shared fleet.
- Purpose Green — Purpose Green operates as a climatetech company.
The Yield Lab Europe is a €50m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.
Show more...Investment focus
- Industry: AgTech, Agriculture, Biotechnology
- Stage:Seed, Series A
- Geography: Ireland, United Kingdom, France
Investor stats
- Total investments: 27
- Round size: Seed $536k–$2M; Series A $3.8M–$10M
- Lead/follow: 19% lead, 81% follow
- Last fund: Likely still investing — raised $54M in 2021
Portfolio highlights
- Skytree — Transforming Carbon Removal for stable, reliable and sustainable CO2 supply
- BiOceanOr — BiOceanOr provides underwater weather stations to measure water quality. Their solutions provide informations from your exploitation in real-time. Receive alerts in real-time and take decisions with their preventive alert system.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Chemical
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, Belgium
Investor stats
- Total investments: 13
- Round size: Series B $4.9M–$24M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
- Avantium — Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.
- F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series C
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 19
- Round size: Series B $5.6M–$30M; Series C $5.5M–$15M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Action Pharma — Providing a surprisingly human shopping experience. Trusted and secure. Millions of domains to choose from.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $3M–$28M; Series B $6.7M–$43M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Nosto — Use Powerful Personalization Made Easy on e-Commerce Platforms. Nosto generates a 10-30% Average Increase in Revenue.
- Minervax — MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein : click to read more
- Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 60
- Round size: Seed $65k–$1.3M; Grant $30k–$2M; Pre-Seed $62k–$440k
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Tryp.com — There is always a reason to go! We use artificial intelligence to find the best travel deals at the lowest price. The algorithm compares and connects flights, trains, and buses to create the perfect multidestination trips with matching hotel offers.
- Curvature AI — Grow your revenue with discounts and special offers selected and optimized by AI.
- Breye Therapeutics — Protecting the Gift of Sight
FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab.FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more;FundersClub Inc. was founded in 2012 and is based in the United States.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: United States, Canada, India
Investor stats
- Total investments: 251
- Round size: Seed $600k–$3.4M; Series A $5M–$23M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — raised $448k in 2019
Portfolio highlights
- Pirros — Pirros is a first real Detail Management System for Architects and Engineers. Store all your details easily. Manage your team's library and continuously improve your details from project to project. Directly integrated with Autodesk Revit
- Florida Street — PIXEL GG INC.
- Shaktimaan — Empowering UPSC aspirants with Kalam's potential to answer, evaluate & personalise your preparation for World's Toughest Exam.
They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.
Show more...Investment focus
- Industry: Software, Information Technology, Internet
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, India
Investor stats
- Total investments: 24
- Round size: Seed $144k–$2.3M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
- Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
- ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.
DSM Venturing provides start-up funding, coaching and support for start-up companies that share our purpose of creating brighter lives for all.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 85
- Round size: Series A $2.5M–$23M; Series B $4.1M–$17M
- Lead/follow: 53% lead, 47% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
- Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
- Incredo — DouxMatok is a food-tech company. They have developed a proprietary technology that enhances the sweetness of sugars with no after taste - preserving the full "sugar experience" customers are looking for. The enhanced sweetness allows for a significant reduction in the consumption of sugar.The company was incorporated in 2014, and itsR&D center is based in Petach-Tikva, Israel.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Series A, Seed
- Geography: Sweden, United States, Denmark
Investor stats
- Total investments: 149
- Round size: Seed $1.3M–$6.4M; Series A $2.7M–$14M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Novatron — A new fusion reactor design for stable plasma confinement and fusion power generation.
- Retein — Aquammodate is a greentech company that produces highly pure water at minimum energy cost.
- Open Payments — Open Payments connects you to multiple banks through one single unified API. This removes the complexity and frictions of many diverse integrations
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 119
- Round size: Seed $2.1M–$18M; Series A $6M–$42M; Series B $9.5M–$67M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
- BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
- Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 60
- Round size: Series A $8M–$50M; Series B $12M–$37M; Series C $10M–$40M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Aura Biosciences — Aura Biosciences is pioneering a first-in-class technology to treat a wide variety of solid tumor types. We are initially pursuing cancers where patients are in need of a transformational change in treatment options, such as choroidal melanoma, so they can avoid choosing between preserving their life or their vision
- LEXEO Therapeutics — LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.
Show more...Investment focus
- Industry: Health Care, Cannabis, Biotechnology
- Stage:Seed, Post-IPO Equity, Pre-Seed
- Geography: Canada, United States, Denmark
Investor stats
- Total investments: 6
- Round size: Post-IPO Equity $6M–$53M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Omura — Discover heat-not-burn technology with Omura's dry herb vaporizer devices. Explore sustainable vaping options for hemp & whole flower CBD.
- Octarine Bio — Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry.
- Martello Technologies — Prioritize and resolve performance problems and optimize the Microsoft 365 and Teams user experience with Martello Vantage DX.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 23
- Round size: Series A $1.3M–$73M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- OssDsign AB — OssDsign was founded in May 2011 by Professor Håkan Engqvist, Dr Thomas Engstrand, Bo Qwarnstrom, Jonas Åberg, Uppsala University AB and other leading clinical, preclinical and materials researchers and engineers. The key people in the company are presented below. OssDsign has in addition developed a network of international experts in ClinicalAffairs, Regulatory and Business Development.
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series C, Series B, Series A
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 121
- Round size: Series A $9M–$35M; Series B $15M–$43M; Series C $15M–$35M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- CVRx — CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
- Binx Health — Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer
- Osteal Therapeutics — Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Robotics, Biotechnology, Industrial Automation
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
ACME is a venture capital firm investing in iconic founders disrupting massive markets.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Canada
Investor stats
- Total investments: 144
- Round size: Seed $1.6M–$8.6M; Series A $3.5M–$24M; Series B $15M–$100M
- Lead/follow: 21% lead, 79% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- BoomPop — Work culture resources, virtual event inspiration, team building ideas, and fresh perspectives on the future work, brought to you by the BoomPop team.
- Slync.io — Slync.io is a SaaS operating platform for global shippers and logistics services providers that deliver higher productivity and process efficiency through intelligent automation. Logistics Orchestration® is an end-to-end service offering that revolutionizes costly back-office processes in global logistics operations. Slync.io connects disparatesystems, ingests structured and unstructured datasets, orchestrates teams, and automates processes seamlessly together delivering unprecedented levels of efficiency for logisticians. Slync.io is a provider of process automation for enterprise supply chains and the global logistics industry. Slync.io is Intelligent Process Automation for Global Logistics.Get connected, visit www.slync.io.
- Reshape Biotech — Reshape Biotech builds lab robots that automate the everyday tasks of microbiologists, from filling plates to analyzing images.
Ferd er et familieeid investeringsselskap som er eid av femte og sjette generasjon Andresen.
Show more...Investment focus
- Industry: Energy, Software, Manufacturing
- Stage:Private Equity, Post-IPO Equity
- Geography: Norway, Sweden, United States
Investor stats
- Total investments: 54
- Round size: Private Equity $11M–$13M; Post-IPO Equity $1M–$38M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — last raise in 2005
Portfolio highlights
- Ludenso — Ludenso is a software developer of AR solutions for the education industry. To make education more creative and engaging, we are giving editors, authors, and teachers the power to bring their learning resources to life through 3D models, animations, videos, and audio support. This is made possible through the Ludenso Studio, where they can createinclusive learning experiences that enables students to learn in their own way.
- wheel.me — The first and only autonomous wheel in the world. The innovation transforms anything into an autonomous mobile robot with minimal effort and without the need to alter its design or form. The company was founded in 2013 and is headquartered in Oslo, Norway.
- Nofence — Nofence is a system virtual fencing for grazing animals. Virtual fencing of livestock has been a concept long discussed in academia. The Norwegian ag-tech startup Nofence has since 2011 developed and patented a solution for virtual fencing that has proven to work. The customers say that this will become a real gamechanger for livestock managementsince pastures can easily be defined by a few clicks on a tablet/smartphone. The herd is then safely fenced in and can be monitored. The system will send notifications if something happens. From the global food security perspective, this solution will make it much easier to utilize the uncultivated land for varied and healthy pasture, and make it possible to produce more food on cultivated land.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Electronics, Biotechnology, Semiconductor
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 3
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- SpectroInlets — SpectroInlets enables measurements of dissolved gases for liquid environments, allowing for new measurement applications.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sound Bioventures is a venture capital fund investing in clinical stage companies.
Show more...Investment focus
- Industry: Medical, Biopharma, Life Science
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 2
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Breye Therapeutics — Protecting the Gift of Sight
People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts. Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.
Show more...Investment focus
- Industry: Health Care, Internet of Things, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 22
- Round size: Pre-Seed $1.4M–$1.5M; Series A $6.1M–$21M
- Lead/follow: 57% lead, 43% follow
Portfolio highlights
- Tiimo — Tiimo helps you manage your daily life and improve your wellbeing. Visualize your day. Improve your routines. Stress less.
- Uniify — Uniify is a no-code customer onboarding software that makes it fast, easy and secure for financial companies to onboard their customers. Save your business time and money, and build onboarding flows for your customers in minutes instead of months.
- LEIA — LEIA is an application that provides postpartum support for new parents.
Four Seasons Ventures, a private equity firm, moves technologies from the U.S. government research agency labs into the private sector.
Show more...Investment focus
- Industry: Legal, Software, Analytics
- Stage:Series B, Series D
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Entigo — Entigo helps to transform your software development processes and improve your operations productivity.
- Affitech AS — Affitech AS engages in the discovery and development of human antibody therapeutics.
- Troux Technologies — Enterprise architecture software and EA tools enable you to map applications, technologies, and capabilities to business strategy. Watch demo.
North-East is an ambitious, global family office helping our families live with wealth in a meaningful way from our offices in Denmark and Singapore.
Show more...Investment focus
- Industry: Therapeutics, Biotechnology, Medical Device
- Stage:Series A
- Geography: Denmark
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Reapplix — Diabetic foot ulcers have a debilitating impact on patients. About 60% of all patients experience a wound that does not heal.
We believe the talent to build great companies comes from anywhere. A global venture capital firm that invests in local founders. As a multi-stage, sector-focused firm, GGV focuses on seed- to growth-stage investments across Social/Internet, Enterprise Tech, and Smart Tech sectors.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series B, Series A, Series C
- Geography: United States, China, Singapore
Investor stats
- Total investments: 588
- Round size: Series A $5M–$50M; Series B $11M–$60M; Series C $10M–$134M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Neon — Postgres made for developers. Easy to Use, Scalable, Cost efficient solution for your next project.
- Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
- Beep Technologies — Beep is creating a universal, modular platform bridging the physical and digital divide, powering smart, contextual & interoperable connectivity across physical touchpoints whilst ensuring true customer privacy by leveraging on decentralised technology.
Rhia Ventures invests in reproductive healthcare solutions that empower women.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Women's
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 11
- Round size: Series A $11M–$15M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Eli — The women's health company providing lifelong insights from your saliva.
- AOA — AOA based in Boston, New York, and London developing cancer diagnostics in the field of women’s health.AOA is a female-led company, is committed to bringing the first accurate early-stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers.
- Twentyeight Health — Your birth control. Delivered to your door. Get a new or re-up existing prescriptions, free & fast deliveries and follow up messaging with doctors. $0 with insurance and starting at $16/pack without.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 154
- Round size: Series A $3.7M–$40M; Series B $15M–$85M; Series C $27M–$57M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- Avalyn Pharma — This does NOT display on the home page
- Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, United Kingdom, Spain
Investor stats
- Total investments: 157
- Round size: Series A $5.2M–$40M; Series B $16M–$58M; Series C $10M–$109M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Allakos — Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatoryresponses. Allakos was founded in 2012 and is headquartered in San Carlos, California.
- BetterVet — At BetterVet.com, we believe pets deserve more than just a regular vet visit. We provide high quality mobile veterinary care. Book pet appointments online now!
- Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 305
- Round size: Series A $3.5M–$23M; Series B $8M–$85M; Series C $8M–$55M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $600M in 2021
Portfolio highlights
- JOKR — Grocery shopping is easier now with JOKR, your instant delivery app. Order your groceries and favorite products in our online supermarket and get them instantly at your door. Download the app now and make your first grocery order on us. Available in IOs and Android. Access www.jokr.com for more info
- Writer — Accelerate growth across every team with the most secure AI platform. We customize generative AI to your workflows, not the other way around.
- Anytype — for those who celebrate trust & autonomy.
Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 866
- Round size: Seed $1.2M–$5.8M; Series A $3.1M–$22M; Series B $6.7M–$50M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Apron — Sort, pay and reconcile your invoices in seconds.
- Worldover — Cosmetic compliance made simple
- Class Companion — Class Companion is a new AI technology that allows professors to provide students with immediate, individualized feedback.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Denmark Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!